# Novigenix

runs an AI-powered blood-transcriptomic platform with published results on early colorectal-cancer detection, and recently secured funding (EUR 1.8 million) to scale its precision-oncology platform and spun out an AI-focused unit to accelerate its immune-intelligence technology.

Source: https://en.bioecon.ru/companies/novigenix/
Updated: 2026-07-20

- Country: Switzerland

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | EUR 1.8 million awarded through the BRECISE IHI grant (2025) | https://ggba.swiss/en/novigenix-secures-eur-1-8-million-to-scale-precision-oncology-platform/, https://novigenix.com/novigenix-ai-awarded-eur-1-8m-in-the-groundbreaking-brecise-ihi-consortium-to-industrialize-ai-powered-liquid-biopsy-for-prediction-of-immunotherapy-response/ |
| Certification | ISO 13485 certified | https://novigenix.com/novigenix-ai-spin-out-to-accelerate-ai-powered-immune-intelligence/ |
| Regulatory approval | Received regulatory approval for COLOX in 2014 | https://novigenix.com/colox-solution/ |
| Headcount | 18 employees | https://novigenix.com |
| Revenue | USD 114 million annual revenue [medium confidence] | https://novigenix.com |
| Production site | Route de la Corniche 3, 1066 Epalinges, Switzerland | https://www.northdata.com/Novigenix%20SA,%20Epalinges/CHE-496.504.999 |

Independent sources: ggba.swiss, northdata.com

## Technologies

- [Multi-cancer early detection (MCED)](https://en.bioecon.ru/technology/multi-cancer-early-detection/)